보령제약 관계사 바이젠셀은 4일 개발 중인 면역항암제가 식품의약품안전처로부터 개발단계 희귀의약품으로 지정됐다고 발표했다.
On the 4th, Boryeong Pharmaceutical's affiliate Weigencell announced that the immune anticancer drug under development has been designated as an orphan drug in the development stage by the Ministry of Food and Drug Safety.